LIF anticorps

N° du produit ABIN2665228

Détail du produit anti-LIF anticorps

Antigène: LIF (Leukemia Inhibitory Factor (LIF))

Reactivité: Humain, Souris

Hôte: Rat

Clonalité: Monoclonal

Conjugué: Cet anticorp LIF est non-conjugé

Application: Flow Cytometry (FACS)

Purification: The antibody was purified by affinity chromatography.

Clone: M1506B09

Isotype: IgG2a

Information d'application

Indications d'application: Optimal working dilution should be determined by the investigator.

Restrictions: For Research Use only

Stockage

Concentration: 0.5 mg/mL

Buffer: Phosphate-buffered solution, pH 7.2, containing 0.09 % sodium azide.

Agent conservateur: Sodium azide

Précaution d'utilisation: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Stock: 4 °C

Stockage commentaire: The antibody solution should be stored undiluted between 2°C and 8°C.

Détails sur LIF

Antigène: LIF (Leukemia Inhibitory Factor (LIF))

Autre désignation: LIF (LIF Produits)

Sujet: Leukemia inhibitory factor (LIF) is a pleiotropic cytokine that belongs to the IL-6 receptor family. It binds to a heterodimeric membrane receptor made up of a LIF-specific subunit, gp190, and the subunit gp130. The LIF complex receptor signals though STAT3 and JAK kinases. LIF expression has been observed in various tissues including the thymus, lung, and neuronal tissue. LIF displays diverse biological effects, but is best known for its ability to inhibit the differentiation of embryonic stem cells in mice and contributes to stem cell self-renewal. It is involved in the induction of hematopoietic differentiation in normal and myeloid leukemia cells, as well as the induction of neuronal cell differentiation. It also regulates mesenchymal to epithelial conversion during kidney development, and also may have a role in immune tolerance at the maternal-fetal interface. LIF can be upregulated by pro-inflammatory cytokines such as TNF-α and IL-17. Elevated levels of LIF have been found in cases of rheumatoid arthritis, neural injury, systemic inflammation, and tuberculosis.

Pathways: Signalistation JAK/STAT, Positive Regulation of Peptide Hormone Secretion, Negative Regulation of Hormone Secretion, Stem Cell Maintenance, Growth Factor Binding